Synphatec

Based in China, Synphatec, operates as a a therapeutics company. Based in Shanghai, China and founded in 2021, Synphatec (Shanghai) Biopharmaceutical Technology Co. , Ltd. is focused on developing innovative therapies for central nervous system disorders.

The funding will support the clinical development of core pipeline assets SP-101 and SP-201, and enhance their technology platforms. Synphatec specializes in developing therapies for central nervous system disorders, particularly targeting conditions like depression and Alzheimer's disease. Their core products include drug candidates SP-101 and SP-102, which are in various clinical development stages. The company utilizes its proprietary i-NaS drug screening platform to identify potential therapies, aiming to improve patient outcomes in collaboration with healthcare providers and pharmaceutical partners.

Revenue generation is expected to come from partnerships and collaborations with pharmaceutical companies, leveraging Synphatec's drug candidates under licensing agreements. As the company progresses through clinical trials, it anticipates engaging in discussions regarding milestone payments associated with trial advancements and product commercialization. The company plans to advance the clinical development of SP-101 and SP-201, optimize its i-NaS and SynX technology platforms, and expand its innovative pipeline to address significant unmet clinical needs.